CN105899230B - 治疗tau病变的方法 - Google Patents

治疗tau病变的方法 Download PDF

Info

Publication number
CN105899230B
CN105899230B CN201480064675.0A CN201480064675A CN105899230B CN 105899230 B CN105899230 B CN 105899230B CN 201480064675 A CN201480064675 A CN 201480064675A CN 105899230 B CN105899230 B CN 105899230B
Authority
CN
China
Prior art keywords
tau
antibody
amino acid
seq
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480064675.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105899230A (zh
Inventor
I·格里斯沃尔德-普伦那
G·帕里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
iPierian Inc
Original Assignee
iPierian Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by iPierian Inc filed Critical iPierian Inc
Priority to CN202010377028.2A priority Critical patent/CN111569063A/zh
Publication of CN105899230A publication Critical patent/CN105899230A/zh
Application granted granted Critical
Publication of CN105899230B publication Critical patent/CN105899230B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480064675.0A 2013-11-27 2014-11-25 治疗tau病变的方法 Expired - Fee Related CN105899230B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010377028.2A CN111569063A (zh) 2013-11-27 2014-11-25 治疗tau病变的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361909965P 2013-11-27 2013-11-27
US61/909,965 2013-11-27
PCT/US2014/067360 WO2015081085A2 (en) 2013-11-27 2014-11-25 Methods of treating a tauopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010377028.2A Division CN111569063A (zh) 2013-11-27 2014-11-25 治疗tau病变的方法

Publications (2)

Publication Number Publication Date
CN105899230A CN105899230A (zh) 2016-08-24
CN105899230B true CN105899230B (zh) 2020-06-09

Family

ID=52232410

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480064675.0A Expired - Fee Related CN105899230B (zh) 2013-11-27 2014-11-25 治疗tau病变的方法
CN202010377028.2A Pending CN111569063A (zh) 2013-11-27 2014-11-25 治疗tau病变的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010377028.2A Pending CN111569063A (zh) 2013-11-27 2014-11-25 治疗tau病变的方法

Country Status (9)

Country Link
US (2) US20160289309A1 (enExample)
EP (1) EP3074420A2 (enExample)
JP (1) JP6629201B2 (enExample)
CN (2) CN105899230B (enExample)
BR (1) BR112016010454A2 (enExample)
CA (1) CA2931396C (enExample)
EA (1) EA038994B1 (enExample)
MX (2) MX384909B (enExample)
WO (1) WO2015081085A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
WO2017100632A1 (en) * 2015-12-11 2017-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
US20190135905A1 (en) * 2017-06-16 2019-05-09 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
CN110770253A (zh) * 2017-06-16 2020-02-07 百时美施贵宝公司 用于治疗tau蛋白病的组合物和方法
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
GB202010652D0 (en) * 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
CN115607684A (zh) * 2021-07-15 2023-01-17 华中科技大学 一种内耳药物纳米载体及其应用
JP2024540226A (ja) * 2021-11-03 2024-10-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体組成物、投薬形態、及び方法
WO2025196217A1 (en) * 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
KR20010015856A (ko) 1997-12-12 2001-02-26 마크로메드 인코퍼레이션 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜)
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
CN103665170A (zh) 2008-12-05 2014-03-26 安吉奥开米公司 肽治疗剂轭合物及其应用
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
WO2011026031A1 (en) * 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
DK2496594T3 (en) * 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
DK2625198T3 (en) * 2010-10-07 2015-09-28 Ac Immune Sa Antibodies that recognize the phosphorylated tau
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SMT201800109T1 (it) * 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
JP6290212B2 (ja) * 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo;Kiran Yanamandra et al.;《Neuron》;20131016;第80卷;第402-414页 *
iPierian Announces Oral Presentation of Tau Antibody Preclinical Efficacy Study Which Showed Significant Reduction in Alzheimer"s Disease Progression;BUSINESS WIRE;《BUSINESS WIRE NEWS》;20131112;第1-2页 *

Also Published As

Publication number Publication date
JP2017504570A (ja) 2017-02-09
WO2015081085A2 (en) 2015-06-04
US20160289309A1 (en) 2016-10-06
MX2021008755A (es) 2021-08-24
CN105899230A (zh) 2016-08-24
BR112016010454A2 (pt) 2017-12-05
MX2016006356A (es) 2016-10-28
EA201690898A1 (ru) 2016-09-30
US20200102375A1 (en) 2020-04-02
WO2015081085A3 (en) 2015-08-06
CA2931396C (en) 2022-09-06
MX384909B (es) 2025-03-14
JP6629201B2 (ja) 2020-01-15
EA038994B1 (ru) 2021-11-18
CA2931396A1 (en) 2015-06-04
CN111569063A (zh) 2020-08-25
EP3074420A2 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
CN105899230B (zh) 治疗tau病变的方法
AU2020203113B2 (en) Anti-complement C1s antibodies and uses thereof
AU2019200448B2 (en) Anti-complement C1s antibodies and uses thereof
US9447180B2 (en) Methods of treating a tauopathy
HK40035696A (en) Methods of treating a tauopathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200609

CF01 Termination of patent right due to non-payment of annual fee